Physician profile
Brinda Gupta
NPI 1821658725
$2,238.50
in general payments reported to CMS, 2019-2025
14 companies · $27.33 in 2025
The $27.33 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $765 · 2023: $666 · 2024: $381 · 2025: $27.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.87 |
| Education | $118.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $440.22 | 2022-2023 | Jakafi |
| Eko Health, INC. | $399.00 | 2021 | |
| Amgen INC. | $201.49 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.82 | 2023 | Iclusig |
| Jazz Pharmaceuticals INC. | $143.12 | 2024 | |
| Seagen INC. | $123.91 | 2022 | |
| Genzyme Corporation | $118.79 | 2022 | |
| Sumitomo Pharma America, INC. | $113.00 | 2023 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $110.53 | 2022 | |
| Abbvie INC. | $106.47 | 2024 | |
| Progenics Pharmaceuticals, INC. | $97.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $94.93 | 2023 | Imfinzi |
| Lilly USA, LLC | $89.95 | 2022 | |
| Janssen Biotech, INC. | $52.73 | 2024-2025 | Tecvayli, Darzalex, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brinda Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.